Leah Sherwood
Articles by Leah Sherwood
This issue includes a Get to Know with Catherine Coombs, MD; a debate on time-limited frontline therapy in CLL, and more.
Nearly all myelofibrosis patients are estimated to develop anemia over the course of the disease.
"There's been a lot of focus on classifications and mutations: they're coming with a lot of force," Dr. Scheinberg said.
Enrolled patients must be aged 75 years or older or aged 18-74 years with specific comorbidities.
The trial will enroll approximately 346 patients with treatment-naive TP53-mutated disease or biallelic 17p deletions.
Dr. Jabbour presented data from the study at the Eleventh Annual Meeting of SOHO.
The Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO) began on Wednesday.
This issue includes BCT Editorial Board highlights, a Get to Know with John DiPersio, MD, PhD; a feature on ctDNA; and more.
In June 2023, the manufacturer of the drug initiated XPORT-MF-034, a pivotal phase III clinical trial.
The US FDA and NMPA have approved IND applications for LBL-034 for the treatment of relapsed or refractory multiple myeloma.
The difference in infection rates between the treatment and placebo groups was not statistically significant.
EMA CHMP adopted a positive opinion recommending the marketing authorization of JZP458.
With a median follow up of 41 months, the three-year PFS and OS rates were 85% and 86%, respectively.
The single-arm, phase II clinical trial enrolled 50 previously untreated patients with a median age of 69 years.
The trial assessed discontinuation of ibrutinib treatment in patients with indolent clinical forms of MCL.
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
In June 2023, a patient death led to the US Food and Drug Administration pausing the iMMagine-1 study.
The CAR-T targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies.
In this video interview, Dr. Mats Ehinger discusses the future of flow cytometry in lymphoma diagnostics.
The FDA has removed the partial clinical hold on the TakeAim Leukemia phase I/II study of emavusertib.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.